Efficacy of a combination modified-live IBR-BVD-PI3- BRSV vaccine + Mannheimia haemolytica toxoid against challenge with virulent bovine respiratory syncytial virus (BRSV) in young calves 60 days of age

Authors

  • Aleksandar Masic Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Brian Sobecki Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Suman Mahan Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Chadwick Brice Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Sally Mattern Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Todd Meinert Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Ignacio Correas Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • Véronique Moulin Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, MI 47001
  • John Ellis College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada

DOI:

https://doi.org/10.21423/bovine-vol55no1p13-19

Keywords:

BRSV, lung lesions, mortality, toxoid, 5-way vaccine

Abstract

Efficacy of attenuated (att) bovine respiratory syncytial virus (attBRSV) as an antigen fraction in a multivalent 6-way vaccine containing modified-live virus and an inactivated Mannheimia haemolytica bacterin-toxoid was given as a single subcutaneous injection, and evaluated by an aerosol challenge by nebulization in young calves with virulent BRSV strain 21 d after vaccination. A total of 32 Holstein calves, seronegative to BRSV and 60 days-of-age at the time of vaccination, were used in the study. Calves were allocated to 2 treatment groups with 16 animals per group, and received either a single dose of a modified-live bovine herpes virus-1, bovine viral diarrhea virus, parainfluenza 3 virus, bovine respiratory syncytial virus vaccine + M. haemolytica bacterin-toxoid, or corresponding placebo formulation without targeted BRSV antigen. Administration of the 6-way vaccine containing BRSV fraction induced significantly higher virus-neutralizing antibody (p=0.0003) and anti-BRSV IgG titers (p=0.0006) in vaccinated animals compared to the placebo group. Consequently, BRSV-vaccinated calves had significantly (p<0.0001) higher arterial partial pressures of oxygen (PaO2), significantly (p<0.0001) lower percentage of lung lesions, and significantly reduced mortality rate (p<0.0001) than did placebo vaccinated calves subsequent to BRSV challenge. Furthermore, there was a 61.2% reduction in virus shedding and duration of shedding (p<0.0001), indicating strong vaccine efficacy.

Downloads

Published

2021-02-01

How to Cite

Masic, A., Sobecki, B., Mahan, S., Brice, C., Mattern, S., Meinert, T., Correas, I., Moulin, V., & Ellis, J. (2021). Efficacy of a combination modified-live IBR-BVD-PI3- BRSV vaccine + Mannheimia haemolytica toxoid against challenge with virulent bovine respiratory syncytial virus (BRSV) in young calves 60 days of age. The Bovine Practitioner, 55(1), 13–19. https://doi.org/10.21423/bovine-vol55no1p13-19

Issue

Section

Articles

Most read articles by the same author(s)